| 1492 |
National Cancer Institute |
Html |
en |
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version |
For acute lymphoblastic leukemia (ALL), the 5-year survival rate rose from 60% to about 90% for children younger than 15 years and from 28% to about 75% for adolescents aged 15–19 years between 1975 and 2010. Get information about risk factors, signs, diagnosis, genomics, survival, risk-based treatment assignment, and induction and postinduction therapy for children and adolescents with newly diagnosed and recurrent ALL. |
| prognostic factors | 0.457078 |
| B-Cell Acute Lymphoblastic | 0.477707 |
| Cancer Statistics Review | 0.442138 |
| B-acute lymphoblastic leukemia | 0.487736 |
| Leukemia Group | 0.457445 |
| children | 0.485859 |
| childhood lymphoblastic leukaemia | 0.461366 |
| acute lymphoblastic leukaemia | 0.619966 |
| acute lymphoblastic leukemias | 0.490719 |
| leukemia cells. | 0.443609 |
| prognostic significance | 0.464566 |
| Nat Genet | 0.45804 |
| leukemia susceptibility gene | 0.452718 |
| Hyperdiploid leukemia cells | 0.447496 |
| et al. | 0.591777 |
| SEER Cancer Statistics | 0.449829 |
| lymphoblastic leukemia consortium | 0.485454 |
| childhood acute leukemias | 0.444646 |
| frank leukemia | 0.449613 |
| Br J Haematol | 0.473302 |
| early T-cell precursor | 0.46793 |
| PUBMED Abstract | 0.469887 |
| concordant leukemia | 0.449352 |
| residual leukemia | 0.447727 |
| Pediatr Blood Cancer | 0.49042 |
|
| acute lymphocytic leukemia | 0.489397 |
| Leukemia Study Group | 0.454229 |
| National Cancer Institute | 0.475056 |
| acute lymphoblastic leukaemias | 0.494907 |
| childhood leukemia | 0.453157 |
| outcome | 0.442439 |
| myeloid leukemia stem | 0.447271 |
| lymphoblastic leukemia risk | 0.49811 |
| lymphoblastic leukaemia aetiology | 0.462653 |
| childhood | 0.471724 |
| Abstract | 0.585405 |
| Acute leukaemia | 0.444978 |
| cancer group | 0.443895 |
| Pediatr Hematol Oncol | 0.438989 |
| Clin Oncol | 0.520227 |
| Pediatric Oncology Group | 0.440216 |
| infant leukemia | 0.443122 |
| acute promyelocytic leukemia | 0.469574 |
| acute lymphoblastic leukemia | 0.925289 |
| acute leukemia | 0.478163 |
| Lymphoblastic Leukemia Treated | 0.486039 |
| Children Leukemia Group | 0.457299 |
| leukemia cells | 0.45331 |
| oncology group | 0.497434 |
|
CLICK HERE |
| 1536 |
National Cancer Institute |
Html |
en |
Laetrile/Amygdalin (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the use of laetrile/amygdalin as a treatment for people with cancer. |
| cancer treatment | 0.52441 |
| cancer cell inhibitors. | 0.542345 |
| intravenous amygdalin treatment | 0.677872 |
| amygdalin occurs | 0.621015 |
| potential anticancer activity | 0.529695 |
| cyanide poisoning | 0.73495 |
| blood cyanide levels | 0.657623 |
| intestinal bacteria | 0.607185 |
| primordial germ cells | 0.521102 |
| purported anticancer activity | 0.532782 |
| oral amygdalin | 0.650441 |
| cancer patients | 0.590892 |
| complete responses | 0.526167 |
| high-dose vitamin supplements | 0.5155 |
| metabolic therapy | 0.516142 |
| U.S.-patented Laetrile | 0.757295 |
| laetrile therapy | 0.736124 |
| amygdalin interacts | 0.616968 |
| laetrile’s breakdown | 0.71917 |
| laetrile practitioners. | 0.705315 |
| anticancer activity | 0.587095 |
| nontoxic intravenous form | 0.531127 |
| specific anticancer properties | 0.534462 |
| intravenous Laetrile | 0.740226 |
| United States | 0.629681 |
|
| positive results | 0.563482 |
| case series | 0.523576 |
| cancer cells | 0.637689 |
| oral maintenance therapy | 0.601513 |
| colon cancer cells | 0.550218 |
| promising cancer therapies | 0.544057 |
| term laetrile | 0.84507 |
| human breast cancer | 0.525831 |
| laetrile treatment. | 0.765844 |
| higher-dose amygdalin therapy | 0.65865 |
| National Cancer Institute | 0.610445 |
| cyanide anion | 0.594345 |
| partial responses | 0.519394 |
| Laetrile supporters | 0.777243 |
| term vitamin B-17 | 0.520783 |
| amygdalin | 0.757648 |
| enzyme beta-glucosidase | 0.562945 |
| anticancer agent | 0.587895 |
| case reports | 0.550533 |
| hydrogen cyanide | 0.876372 |
| cyanide group | 0.578561 |
| laetrile | 0.994496 |
| chemical amygdalin | 0.642935 |
| cancer | 0.720035 |
|
CLICK HERE |
| 1548 |
National Cancer Institute |
Html |
en |
Breast Cancer Screening (PDQ®)–Patient Version |
Mammogram, clinical breast exam (CBE), and MRI (magnetic resonance imaging) tests are used to screen for breast cancer. Learn about this and other tests that have been studied to detect or screen for breast cancer in this expert-reviewed summary. |
| cancer screening methods | 0.42533 |
| fast-growing breast cancer | 0.440825 |
| ongoing clinical trials | 0.389452 |
| following PDQ summaries | 0.382952 |
| PDQ cancer information | 0.474492 |
| following PDQ summary | 0.39258 |
| breast fluid | 0.391775 |
| common screening test | 0.39988 |
| routine breast cancer | 0.436027 |
| clinical trials | 0.527662 |
| cancer information summary | 0.430839 |
| breast tissue sampling | 0.438767 |
| breast cancer prevention | 0.479726 |
| test results | 0.400913 |
| test | 0.410305 |
| Yearly MRI screening | 0.382239 |
| NCI PDQ cancer | 0.406053 |
| women | 0.476763 |
| PDQ Screening | 0.392324 |
| stage breast cancer | 0.437499 |
| screening tests | 0.377685 |
| breast cancer diagnosis | 0.443317 |
| clinical breast exams | 0.420114 |
| regular breast | 0.389266 |
| Cancer Information Service | 0.377203 |
|
| breast cancers | 0.414043 |
| denser breast tissue | 0.419753 |
| breast duct | 0.396464 |
| breast tissue | 0.495937 |
| Prevention Editorial Board | 0.379673 |
| annual screening mammogram | 0.410065 |
| National Cancer Institute | 0.431327 |
| Cancer Screening Overview | 0.412144 |
| breast cancer benefit | 0.435864 |
| breast biopsy result | 0.412172 |
| lymph vessels | 0.375923 |
| breast tumors | 0.395991 |
| breast cancer screening | 0.602061 |
| Cancer screening trials | 0.429799 |
| clinical breast exam | 0.420394 |
| breast cancer | 0.970368 |
| clinical breast | 0.421091 |
| dense breast tissue | 0.418481 |
| PDQ summary | 0.443066 |
| false-positive screening mammogram | 0.452332 |
| breast self-exams | 0.40904 |
| cancer information summaries | 0.380757 |
| comprehensive cancer information | 0.380439 |
| screening mammogram | 0.469345 |
|
CLICK HERE |
| 1565 |
National Cancer Institute |
Html |
null |
Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of lip and oral cavity cancer. |
|
|
CLICK HERE |
| 1669 |
National Cancer Institute |
Html |
en |
Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of childhood craniopharyngioma |
| evidence | 0.541909 |
| subtotal resection | 0.652496 |
| intensity-modulated photon therapy | 0.593647 |
| Aylwin et al. | 0.579904 |
| Merchant TE | 0.567828 |
| radiation therapy section | 0.596714 |
| PDQ cancer information | 0.54907 |
| Conventional radiation therapy | 0.591705 |
| Tumors Treatment Overview | 0.55265 |
| radiation dose | 0.548781 |
| Int J Radiat | 0.614894 |
| photon radiation therapy | 0.573627 |
| craniopharyngiomas | 0.555197 |
| cancer information summary | 0.541422 |
| Radiat Oncol Biol | 0.7952 |
| irradiated craniopharyngioma | 0.570882 |
| standard fractionated radiation | 0.630603 |
| Tan et al. | 0.575816 |
| conformal radiation treatments | 0.560832 |
| proton therapy | 0.60593 |
| tumor control | 0.588032 |
| common solid tumor | 0.565687 |
| recurrent cystic tumor | 0.550194 |
| radiation therapy | 0.986329 |
| Morisako et al. | 0.5808 |
|
| spare normal tissue | 0.555535 |
| Neurosurg Focus | 0.546254 |
| et al. | 0.839112 |
| complete resection | 0.561879 |
| magnetic resonance imaging | 0.576707 |
| newer radiation technologies | 0.623865 |
| gross-total resection | 0.656285 |
| brain tumor treatment | 0.599377 |
| residual craniopharyngioma | 0.590756 |
| pediatric craniopharyngioma | 0.701375 |
| stereotactic radiation therapy | 0.599058 |
| PUBMED Abstract | 0.577489 |
| craniopharyngioma cyst growth | 0.621968 |
| childhood craniopharyngioma | 0.72734 |
| Abstract | 0.609429 |
| external-beam radiation therapy | 0.569508 |
| pediatric brain tumors | 0.558017 |
| Sterkenburg et al. | 0.578437 |
| Oncol Biol Phys | 0.807866 |
| Neurosurg Pediatr | 0.63126 |
| recurrent craniopharyngioma | 0.572364 |
| papillary craniopharyngioma | 0.570471 |
| tumor | 0.617686 |
| craniopharyngioma | 0.809351 |
|
CLICK HERE |
| 2020 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de cuello uterino (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre los factores que aumentarían el riesgo de presentar cáncer de cuello uterino y los enfoques que ayudarían a la prevención de esta enfermedad. |
| cervical intra-epithelial neoplasia | 0.302624 |
| Obstet Gynecol | 0.303555 |
| Lancet Infect Dis | 0.302739 |
| vacuna qHPV | 0.302144 |
| VPH vs | 0.303877 |
| cervical carcinoma | 0.305011 |
| cáncer invasor | 0.318393 |
| González A | 0.303459 |
| VPH oncógenos | 0.304066 |
| American Cancer Society | 0.303348 |
| case-control study | 0.30305 |
| Costa Rica Vaccine | 0.302774 |
| cervical neoplasia | 0.303702 |
| Schiffman M | 0.30246 |
| without cervical carcinoma | 0.302609 |
| risk factors | 0.303566 |
| collaborative reanalysis | 0.305986 |
| International Collaboration | 0.302415 |
| Estados Unidos | 0.303742 |
| vacuna 9vHPV | 0.303595 |
| cancer in | 0.308272 |
| Natl Cancer Inst | 0.304144 |
| cervical cancer | 0.371053 |
| vacuna vph | 0.305378 |
| North American multicohort | 0.3021 |
|
| 9-valent hpv vaccine | 0.303034 |
| VPH Población Estimación | 0.304092 |
| Quadrivalent HPV Vaccination | 0.302755 |
| human papillomavirus | 0.353991 |
| vacuna nanovalente vlp | 0.302596 |
| risk among hiv-infected | 0.30327 |
| Bosch FX | 0.30227 |
| Castle PE | 0.302445 |
| Muñoz N | 0.303856 |
| Costa Rica | 0.303541 |
| collaboration prospective study | 0.303065 |
| Immune Defic Syndr | 0.302422 |
| multicohort collaboration prospective | 0.302636 |
| Adverse Pregnancy Outcomes | 0.302449 |
| Acquir Immune Defic | 0.302422 |
| epidemiological studies | 0.313912 |
| with cervical carcinoma | 0.302983 |
| vacuna vph-16 l1 | 0.302668 |
| cervical intraepithelial neoplasia | 0.304671 |
| cuello uterino | 0.985138 |
| American multicohort collaboration | 0.302442 |
| Cancer In young | 0.302413 |
| vacuna bivalente tipo | 0.302487 |
| cancer risk | 0.305603 |
|
CLICK HERE |
| 2022 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de cuello uterino (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre los exámenes que se utilizan para detectar el cáncer de cuello uterino. |
| siguientes grupos | 0.30039 |
| PDQ Exámenes | 0.300773 |
| Physician Data Query | 0.301635 |
| libre uso | 0.300195 |
| cuello uterino | 0.99515 |
| prevención revisa | 0.300275 |
| largo plazo | 0.300411 |
|
| principal factor | 0.302387 |
| información ayuda | 0.300455 |
| National Cancer Institute | 0.300349 |
| siguientes riesgos | 0.300249 |
| siguientes sumarios | 0.301285 |
| Instituto Nacional | 0.300751 |
|
CLICK HERE |
| 2033 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de próstata (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre los factores que pueden influir en el riesgo de cáncer de próstata y sobre la investigación dirigida a la prevención de esta enfermedad. |
| Thompson IM | 0.314327 |
| accessed july | 0.302228 |
| results from | 0.303565 |
| Connolly JM | 0.303382 |
| Prostate Cancer Events | 0.317969 |
| habitantes hombres | 0.302425 |
| Cancer Statistics Review | 0.317133 |
| Ross RK | 0.305958 |
| Sin embargo | 0.309562 |
| grasas animales | 0.30255 |
| American Cancer Society | 0.316034 |
| dietary fat | 0.303757 |
| tumores gleason | 0.303142 |
| productos lácteos | 0.302873 |
| Cancer Rates | 0.308415 |
| EI aumento | 0.303513 |
| EI riesgo | 0.304572 |
| Prostate specific | 0.303323 |
| Estados Unidos | 0.302842 |
| Natl Cancer Inst | 0.462208 |
| Gleason DF | 0.304482 |
| cancer prevention trial | 0.348935 |
| menor riesgo | 0.303815 |
| Prostate Cáncer Prevention | 0.30803 |
| SEER Cancer Statistics | 0.317438 |
|
| investigation into cancer | 0.307885 |
| Bernstein L | 0.303522 |
| prostate cancer prevention | 0.326581 |
| Prostate Prevention Trial | 0.304615 |
| Tangen CM | 0.304256 |
| Kristal AR | 0.303247 |
| EI Prostate Cancer | 0.311391 |
| United States | 0.314913 |
| Prostate Cancer Clinical | 0.31207 |
| Cancer Facts | 0.309636 |
| Kolonel LN | 0.303682 |
| prostate lncap tumors | 0.303282 |
| among japanese | 0.304198 |
| Nutr Cancer | 0.308752 |
| National Cancer Institute | 0.326849 |
| Epidemiol Biomarkers Prev | 0.307319 |
| dutasterida vs | 0.303715 |
| antecedentes familiares | 0.303019 |
| fatty acids | 0.303826 |
| Prostate Cancer Survey | 0.310986 |
| Prostate visualization studies | 0.303528 |
| grasas alimenticias | 0.316785 |
| prostate cancer | 0.996017 |
| Rose DP | 0.305512 |
|
CLICK HERE |
| 2049 |
National Cancer Institute |
Html |
es |
Trasplantes de células madre formadoras de sangre |
Hoja informativa que explica los procedimientos, paso a paso, del trasplante de médula ósea y del trasplante de células madre de sangre periférica, así como sus riesgos y beneficios. |
| células madre | 0.995824 |
| efecto gvt | 0.300369 |
| trasplante autólogo | 0.304497 |
| PBSCT alogénicos | 0.300755 |
| llamadas antÃgenos | 0.300572 |
| frecuencia células madre | 0.306001 |
| bone marrow transplantation | 0.300883 |
| raros casos | 0.300403 |
| Sin embargo | 0.307734 |
| catéter venoso central | 0.300806 |
| Programa Nacional | 0.300971 |
| llamadas células madre | 0.30624 |
| largo plazo | 0.300324 |
| causa disminución | 0.300351 |
| seguro médico | 0.300814 |
|
| cubre be | 0.300325 |
| paciente transfusiones | 0.301172 |
| HLA compatibles mejora | 0.301344 |
| idéntico. sin embargo | 0.300876 |
| antÃgenos hla | 0.303269 |
| stem cell transplantation | 0.300928 |
| programa be | 0.300461 |
| posibles efectos | 0.301054 |
| linfocitos t". | 0.3004 |
| atacan. más | 0.300461 |
| GVHD aguda | 0.300451 |
| corto plazo | 0.30031 |
| sangre. solo | 0.300435 |
| usa dosis | 0.301797 |
| tipo hla | 0.300841 |
|
CLICK HERE |
| 16184 |
National Cancer Institute |
Html |
es |
Manejo de costos y de información médica |
Las personas con cáncer y sus familias pueden enfrentarse a mayores retos económicos. El tratamiento de cáncer puede ser muy caro, aun cuando se tenga seguro. Aprenda cómo mantener la cuenta de tratamientos y de pruebas, de formularios y cobros, y más. |
| cuáles tratamientos | 0.380156 |
| Busque programas | 0.344502 |
| información médica clave. | 0.356222 |
| médico muestras | 0.355273 |
| expediente personal | 0.405493 |
| Health Information Management | 0.361343 |
| importante cuál sistema | 0.365142 |
|
| mayores retos | 0.375386 |
| Busque asistencia | 0.353171 |
| Busque formas | 0.327721 |
| Sociedad Americana | 0.349375 |
| busque ayuda | 0.333405 |
| seguro médico | 0.91222 |
| mano. revise cuáles | 0.413273 |
|
CLICK HERE |